论文部分内容阅读
目的:为了增加结肠炎患者的治疗效果,分析和探讨应用美沙拉嗪联合双歧杆菌三联活菌治疗的价值和意义。方法:通过随机数字表的方法从2016年3月至2017年3月来我院治疗的结肠炎患者中选取100例作为研究对象并通过抛硬币的方法对其进行分组,其中仅接受美沙拉嗪口服治疗的设为对照组,接受美沙拉嗪联合双歧杆菌三联活菌治疗的设为试验组,比较不同用药方案对疗效影响。结果:此次研究结果显示,尽管试验组和照组患者都取得一定的治疗效果,但是与对照组相比试验组患者的治疗总有效率明显占据优势,且比较差异具有统计学意义(P<0.05)。结论:采用美沙拉嗪联合双歧杆菌三联活菌片治疗结肠炎患者,有利于提高治疗效果,促进肠黏膜恢复,效果显著,值得临床应用。
Objective: In order to increase the therapeutic effect of colitis patients, analyze and explore the value and significance of the application of Mesalazine combined with Bifidobacterium triple viable bacteria. Methods: 100 patients with colitis treated in our hospital from March 2016 to March 2017 were selected as research subjects by random number table method and grouped by coin-tossing method, in which only mesalazine Oral treatment as the control group, receiving Mesalazine combined with Bifidobacterium triple viable bacteria treatment group as the experimental group to compare the effect of different drug regimens. Results: The results of this study showed that although the treatment group and the control group achieved certain therapeutic effects, the total effective rate of the experimental group was obviously superior to that of the control group, and the difference was statistically significant (P < 0.05). Conclusion: Mesalazine combined with Bifidobacterium triple live viable tablets in patients with colitis is conducive to improving the therapeutic effect and promoting the recovery of intestinal mucosa, the effect is significant and is worth clinical application.